Skip to content

Preliminary evaluation of the clinical efficacy of the Xiefei Lishui Formulain intervening in post-infarction heart failure

Preliminary evaluation of the clinical efficacy of the Xiefei Lishui Formulain intervening in post-infarction heart failure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000429
Enrollment
Unknown
Registered
2025-02-27
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure after Myocardial Infarction

Interventions

treatment group:Standardized Western medicine treatment + Xiefei LIshui Formula*2 weeks
control group:Standardized western medicine treatment*2weeks

Sponsors

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-80 years old, gender is not limited; (2) Meet the western medical diagnosis of post-infarction heart failure in western medicine; (3) Chinese medicine diagnosis of Qi deficiency and water stopping; (4) Cardiac function class II-III (NYHA); (5) Signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Undergoing surgical treatment during the planned trial; (2) Suffering from primary valvular disease, cardiomyopathy, severe cardiac arrhythmia, cardiogenic shock, acute myocardial infarction; (3) Having a serious primary haematological disorder or suffering from a serious psychiatric disorder; (4) Serum creatinine level > 221 µmol/L; (5) Alanine aminotransferase or aspartate aminotransferase level > 3 times the upper limit of normal;(6) Poorly controlled blood pressure, with systolic blood pressure exceeding 180 mmHg or diastolic blood pressure exceeding 110 mmHg; (7) Pregnancy or breastfeeding; (8) Known or suspected allergy to the study medication; (9) Concurrently participating in a clinical study of other medications; (10) Any other condition that, in the judgement of the investigator, makes participation in the trial unsuitable.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;

Secondary

MeasureTime frame
left ventricular fraction shortening;TCM syndrome evaluation;Minnesota Heart Failure Quality of Life ScaleMLHFQ;left ventricular end diastolic diameter;left ventricular end systolic diameter;

Countries

China

Contacts

Public ContactQiuShenglei

Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University

choushenglei@bjzhongyi.com13426241268

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026